|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOMO1 |
Gene summary for NOMO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOMO1 | Gene ID | 23420 |
| Gene name | NODAL modulator 1 | |
| Gene Alias | Nomo | |
| Cytomap | 16p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q15155 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23420 | NOMO1 | S016 | Human | Liver | HCC | 5.54e-11 | 4.68e-01 | 0.2243 |
| 23420 | NOMO1 | S027 | Human | Liver | HCC | 1.81e-06 | 6.00e-01 | 0.2446 |
| 23420 | NOMO1 | S028 | Human | Liver | HCC | 3.23e-16 | 5.65e-01 | 0.2503 |
| 23420 | NOMO1 | S029 | Human | Liver | HCC | 6.32e-20 | 8.26e-01 | 0.2581 |
| 23420 | NOMO1 | C04 | Human | Oral cavity | OSCC | 6.33e-06 | 2.11e-01 | 0.2633 |
| 23420 | NOMO1 | C21 | Human | Oral cavity | OSCC | 7.74e-09 | 2.06e-01 | 0.2678 |
| 23420 | NOMO1 | C30 | Human | Oral cavity | OSCC | 1.19e-23 | 7.25e-01 | 0.3055 |
| 23420 | NOMO1 | C38 | Human | Oral cavity | OSCC | 9.35e-07 | 3.66e-01 | 0.172 |
| 23420 | NOMO1 | C43 | Human | Oral cavity | OSCC | 6.33e-04 | 1.48e-01 | 0.1704 |
| 23420 | NOMO1 | C46 | Human | Oral cavity | OSCC | 6.87e-04 | 9.61e-02 | 0.1673 |
| 23420 | NOMO1 | C51 | Human | Oral cavity | OSCC | 2.82e-11 | 4.21e-01 | 0.2674 |
| 23420 | NOMO1 | C57 | Human | Oral cavity | OSCC | 3.24e-05 | 1.37e-01 | 0.1679 |
| 23420 | NOMO1 | C06 | Human | Oral cavity | OSCC | 1.28e-06 | 7.26e-01 | 0.2699 |
| 23420 | NOMO1 | C07 | Human | Oral cavity | OSCC | 4.58e-04 | 4.42e-01 | 0.2491 |
| 23420 | NOMO1 | C08 | Human | Oral cavity | OSCC | 1.74e-10 | 2.90e-01 | 0.1919 |
| 23420 | NOMO1 | C09 | Human | Oral cavity | OSCC | 1.38e-06 | 1.95e-01 | 0.1431 |
| 23420 | NOMO1 | LP15 | Human | Oral cavity | LP | 3.19e-08 | 5.38e-01 | 0.2174 |
| 23420 | NOMO1 | SYSMH1 | Human | Oral cavity | OSCC | 1.60e-03 | 1.18e-01 | 0.1127 |
| 23420 | NOMO1 | SYSMH2 | Human | Oral cavity | OSCC | 1.54e-03 | 2.20e-01 | 0.2326 |
| 23420 | NOMO1 | SYSMH3 | Human | Oral cavity | OSCC | 4.39e-02 | 1.72e-01 | 0.2442 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007178 | Colorectum | AD | transmembrane receptor protein serine/threonine kinase signaling pathway | 99/3918 | 355/18723 | 9.92e-04 | 9.28e-03 | 99 |
| GO:00071781 | Colorectum | MSS | transmembrane receptor protein serine/threonine kinase signaling pathway | 86/3467 | 355/18723 | 4.04e-03 | 2.95e-02 | 86 |
| GO:00071782 | Colorectum | FAP | transmembrane receptor protein serine/threonine kinase signaling pathway | 81/2622 | 355/18723 | 4.28e-06 | 1.46e-04 | 81 |
| GO:0090092 | Colorectum | FAP | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 52/2622 | 256/18723 | 3.33e-03 | 2.44e-02 | 52 |
| GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
| GO:00071789 | Oral cavity | OSCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 165/7305 | 355/18723 | 2.31e-03 | 1.02e-02 | 165 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOMO1 | SNV | Missense_Mutation | c.1421G>C | p.Arg474Thr | p.R474T | Q15155 | protein_coding | deleterious(0.04) | benign(0.104) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| NOMO1 | SNV | Missense_Mutation | rs771995798 | c.3130N>A | p.Asp1044Asn | p.D1044N | Q15155 | protein_coding | tolerated(0.14) | benign(0.223) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| NOMO1 | SNV | Missense_Mutation | rs779029500 | c.2660N>C | p.Asp887Ala | p.D887A | Q15155 | protein_coding | deleterious(0.04) | benign(0.057) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
| NOMO1 | SNV | Missense_Mutation | c.1084N>C | p.Asp362His | p.D362H | Q15155 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NOMO1 | SNV | Missense_Mutation | c.3202N>C | p.Glu1068Gln | p.E1068Q | Q15155 | protein_coding | tolerated(0.07) | possibly_damaging(0.702) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NOMO1 | SNV | Missense_Mutation | rs763791304 | c.1456N>G | p.Leu486Val | p.L486V | Q15155 | protein_coding | tolerated(1) | benign(0) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
| NOMO1 | SNV | Missense_Mutation | novel | c.387C>A | p.Phe129Leu | p.F129L | Q15155 | protein_coding | deleterious(0.01) | benign(0.292) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NOMO1 | SNV | Missense_Mutation | novel | c.415N>A | p.Gly139Arg | p.G139R | Q15155 | protein_coding | deleterious(0.01) | benign(0.103) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NOMO1 | SNV | Missense_Mutation | c.2998N>C | p.Glu1000Gln | p.E1000Q | Q15155 | protein_coding | deleterious(0.04) | possibly_damaging(0.518) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| NOMO1 | SNV | Missense_Mutation | c.1084N>A | p.Asp362Asn | p.D362N | Q15155 | protein_coding | tolerated(0.17) | probably_damaging(0.922) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |